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Attention-deficit/hyperactivity disorder (ADHD) is a common and highly heritable disorder, but
specific genetic factors underlying risk remain elusive. To assess the role of structural
variation in ADHD, we identified 222 inherited copy number variations (CNVs) within 335 ADHD
patients and their parents that were not detected in 2026 unrelated healthy individuals.
Although no excess CNVs, either deletions or duplications, were found in the ADHD cohort
relative to controls, the inherited rare CNV-associated gene set was significantly enriched for
genes reported as candidates in studies of autism, schizophrenia and Tourette syndrome,
including A2BP1, AUTS2, CNTNAP2 and IMMP2L. The ADHD CNV gene set was also
significantly enriched for genes known to be important for psychological and neurological
functions, including learning, behavior, synaptic transmission and central nervous system
development. Four independent deletions were located within the protein tyrosine phospha-
tase gene, PTPRD, recently implicated as a candidate gene for restless legs syndrome, which
frequently presents with ADHD. A deletion within the glutamate receptor gene, GRM5, was
found in an affected parent and all three affected offspring whose ADHD phenotypes closely
resembled those of the GRM5 null mouse. Together, these results suggest that rare inherited
structural variations play an important role in ADHD development and indicate a set of putative
candidate genes for further study in the etiology of ADHD.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD), the
most common neuropsychiatric disorder in children,
with a 5.2% worldwide pooled prevalence rate,
1
causes significant academic, behavioral and social
impairment throughout the life span.
2,3 The pheno-
type consists of extreme manifestations of continuous
traits, including hyperactivity, impulsivity, and dys-
function in executive and self-regulatory skills that
involve working memory, temporal organization,
planning, organizing, maintaining focus, effort and
motivation.
4,5
Brain studies of patients with ADHD have shown
abnormalities in frontal-striatal and cerebellar circui-
try.
6,7 Although dopaminergic and noradrenergic
medications are clinically effective,
8 animal models
provide support for the involvement of additional
molecular pathways.
9 Twin studies estimate a herit-
ability of up to 90%,
10 indicating a substantial genetic
contribution. However, genetic association studies
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conferring major risk.
10,11 ADHD comorbidity occurs
in many neuropsychiatric disorders, including aut-
ism, Tourette syndrome and in children with schizo-
phrenic parents.
12,13
Recently, investigations of autism
14–16 and schizo-
phrenia
17–21 have implicated de novo and/or rare copy
number variations (CNVs) as being potentially patho-
genic in these disorders. These findings are consistent
with a genetic model where any of a large number of
individually rare mutations of recent origin, and
affecting a substantial number of genes involved in
neurodevelopment, can contribute to disease predis-
position. Given the highly heritable and variable
nature of ADHD, we therefore hypothesized that
individually rare and inherited structural variants
might contribute to disease risk in ADHD, and that
such variants are likely enriched within genes
involved in neurological processes and neuropsychia-
tric disease. To our knowledge, this is the first report
investigating the role of structural variants in ADHD.
Materials and methods
ADHD population
Attention-deficit/hyperactivity disorder families were
recruited from pediatric and behavioral health clinics
in the Philadelphia area. Inclusion criteria included
families of European descent with an ADHD proband
(age 6–18). Exclusionary criteria included prematur-
ity (<36 weeks), mental retardation, major medical
and neurological disorders, pervasive developmental
disorder, psychoses and major mood disorders. Blood
collected from ADHD families was sent to the Rutgers
University Cell and DNA Repository in New Jersey
where lymphoblastoid cell lines were developed.
Subsequently, DNA was extracted and returned to
our laboratory for genotyping.
Healthy control population
Healthy control individuals were recruited from the
Philadelphia region through the Hospital’s Health
Care Network, including four primary care clinics and
several group practices and outpatient practices that
performed well child visits. Eligibility criteria for this
study included both of the following: disease-free
children (age range: 6–18 years) and parents of these
children who had high-quality, genome-wide geno-
typing data from blood samples with no serious
underlying medical disorder, including, but not
limited to neurodevelopmental disorders, cancer,
chromosomal abnormalities and known metabolic
or genetic disorders. DNA samples from a small set
of parents of the participating children were also
genotyped and used to assess CNV heritability
patterns. A total of 2026 individuals passed all quality
control measures and qualified for the study. All
participants and/or their parents signed an informed
consent permitting the use of their genotypes and
health-care records for the study. Ancestry informa-
tive markers available on the HumanHap550
BeadChip
22 were used to evaluate these 2026 partici-
pants to confirm ethnicity.
Measures
A child psychiatrist assessed diagnostic status of
ADHD probands by administering the Schedule for
Affective Disorders and Schizophrenia for School Age
Children -IV Revised (K-SADS P-IVR).
23 Intraclass
correlations between raters for the diagnostic symp-
toms of the major disorders were assessed through
videotape reviews. Parental ADHD was assessed
using the ADHD Self-Report Scale.
24,25 Parents pro-
vided consent and children assent.
Genotyping
All samples were uniformly genotyped at the Center
for Applied Genomics at the Children’s Hospital of
Philadelphia. DNA samples were surveyed for quality
both by optical density spectrophotometry and the
PicoGreen assay (Molecular Probes, Eugene, OR,
USA).
26 Samples judged to be of sufficient quality
for genotyping were assayed on the Illumina Infinium
II HumanHap550 BeadChip (Illumina, San Diego, CA,
USA) as previously described.
27 As BeadChip images
were collected, intensity values were determined for
all instances of each bead type, and data files were
created that summarized intensity values for each
bead type. A bead pool manifest was loaded into
BeadStudio along with intensity data for the samples.
BeadStudio uses a normalization algorithm to mini-
mize BeadChip to BeadChip variability. Once
the normalization was complete, a clustering
algorithm was used to evaluate cluster positions
for each locus and assign individual genotypes. logR
ratios (LRRs) and B allele frequencies were calculated
for every single nucleotide polymorphism (SNP)
based on these clusters and the genotype of each SNP.
CNV detection and analysis
The Illumina BeadStudio 3.0 software package was
used for initial CNV detection analysis. LRRs and B
allele frequencies were first exported from BeadStu-
dio. LRR values were used as an additional sample-
wide genotype quality control measure, and LRRs
with a standard deviation above 0.35 were excluded
from the study. Chromosomes were segmented on the
basis of LRRs, using the circular binary segmentation
algorithm implemented in the R statistical package
module DNAcopy 1.7 (http://www.bioconductor.org/).
We used the reference clusters for each SNP that were
supplied by Illumina from a set of HapMap samples.
As these samples are a mixture of males and females,
the Log R Ratio distribution for the X chromosome
differs from that of the autosomal chromosomes.
Accordingly, differing thresholds were chosen based
on known samples with X chromosome deletions and
duplications. For autosomal chromosomes, we used
threshold of acceptance values of  2,  0.3 and 0.25
for the mean LRRs of potential homozygous deletions,
hemizygous deletions and duplications, respectively.
For males, X chromosome thresholds of  2 and 0.1
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respectively. For females, X chromosome thresholds
of  1.5,  0.1 and 0.6 were used for homozygous
deletions, hemizygous deletions and duplications,
respectively. Initial CNV calls were then further
filtered by their B allele frequency distribution
patterns. Autosomal and female chromosome X B
allele frequency patterns for duplications and homo-
zygous deletions were required to fit a three-copy
mode more closely than a two-copy mode. In
addition, paucity of AB alleles in the segment was a
requirement for calling the segment a hemizygous
deletion. For comparative purposes, two CNVs were
considered the same or non-unique if their over-
lapping region contained at least 80% of the SNPs
comprising each CNV. We limited the CNV set for
consideration to those spanning X10 consecutive
SNPs after conducting a trial of >200 experimentally
validated CNVs that showed >99% accuracy for our
CNV prediction method using this threshold. In
addition, all CNVs meeting quality and experimental
design metrics were independently assessed by
inspection of each BeadStudio visualization.
Literature analysis
Literature analysis used the set of 175 non-olfactory
receptor genes overlapping CNVs unique to ADHD
probands relative to controls. Literature records
associated with these genes were assessed by an
expert reviewer to determine whether genes had been
previously suggested as candidate genes in neurop-
sychiatric or neural functioning disorders. Accepted
evidence was restricted to significant or suggestive
findings in genetic association or structural variation
studies performed either as gene-specific surveys or
genome-wide. To confirm the literature review pro-
cess, we determined whether biomedical literature
mentioning the ADHD CNV gene set preferentially
referred to other neuropsychiatric disorders. As the
ADHD gene set was acquired using an independent
genetic technique that had no memory of prior
studies, a null hypothesis would predict that MED-
LINE abstracts mentioning the 175 ADHD genes
would not be enriched for terms related to autism or
schizophrenia, the two disorders comorbid with
ADHD with sufficient literature sampling sizes. For
this process, sets of genes co-mentioned with terms
related to autism or schizophrenia in MEDLINE
abstracts and abstract metadata were identified, using
the literature mining tool FABLE (http://fable.chop.
edu), the Phenopedia tool of the gene resource HuGE
Navigator (http://hugenavigator.net/), and for autism
queries, the autism gene database AutDB (http://
www.mindspec.org/autdb.html). FABLE query terms
used were ‘autism’ and/or ‘schizophrenia’, with or
without terms relating to structural variation (see
Table 1). HuGE Navigator concepts used were Autistic
Disorder, Schizophrenia, and for controls, Meningio-
ma, Astrocytoma, Parkinson Disease, and Alzheimer
Disease. For AutDB, we used all genes listed as
candidates as the test group. For all three resources,
the sets of genes implicated in the queried diseases
were tested for significantly enriched representation
of ADHD CNV genes using the single-sample propor-
tions test.
In silico functional analysis
Functional and pathway analyses were carried out
using the Ingenuity Pathway Analysis software
package (http://www.ingenuity.com). Gene Ontology
(GO) analysis was carried out using the Explain
software from Biobase, as part of the Biobase Knowl-
edgebase (http://bkl.biobase.de/cgi-bin/bkl/idb/1.0/
login.cgi?previous_url=searchengine/start.cgi). For
both sets of analyses, RefSeq genes overlapping the
rare and inherited ADHD CNVs were extracted and
input into the requisite pathway analysis models.
Table 1 Enrichment of ADHD CNV genes in autism and schizophrenia candidate genes
Resource Query Genes matching
query
ADHD genes
in query
Z-score P-value
FABLE Autism 1003 10 1.14 0.127
FABLE Schizophrenia 2516 29 13.19 <0.001
FABLE Autism OR schizophrenia 2857 32 11.66 <0.001
FABLE Autism AND CNV
a 438 6 13.35 <0.001
FABLE Schizophrenia AND CNV
a 998 11 5.73 <0.001
FABLE Autism OR schizophrenia AND CNV
a 1259 16 14.81 <0.001
HuGE navigator Autistic disorder 111 1 INS
b INS
b
HuGE navigator Schizophrenia 505 9 24.82 <0.001
HuGE navigator Autistic disorder OR schizophrenia 561 9 20.46 <0.001
AutDB All genes 137 5 42.25 <0.001
SchizophreniaGene All genes 762 10 12.93 <0.001
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNV, copy number variation.
aQuery terms representing the concept of CNV: (genetics OR genomics) AND (‘structural variation’ OR ‘copy number’ OR
association OR deletion OR duplication OR translocation).
bINS, insufficient sample size to determine significance.
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Fluorescence in situ hybridization. Fluorescence in
situ hybridization (FISH) validation of the GRM5
deletion was performed on metaphase spreads
prepared from the participant-derived lympho-
blastoid cell lines using standard methodology.
Chromosomes were visualized by counter staining
with 4,6-diamidino-2-phenylindole. FISH was
performed using fosmid W12-2219g4 and BAC RP11-
697e14. FISH analysis was carried out as previously
described.
28 Bacterial artificial chromosomes and
fosmids were isolated using the UltraClean plasmid
kit (MoBio Labs Inc., Carlsbad, CA, USA) and probes
were labeled with Spectrum Red or Green (Abbott
Molecular Inc., IL, USA) by nick translation. FISH
images were captured using MacProbe software
(Applied Imaging, San Jose, CA, USA).
Real-time quantitative PCR. Primers and probes used
to detect PTPRD CNVs were designed using Primer
Express software (Applied Biosystems, Foster City
CA, USA). Primers were purchased from Integrated
DNA Technologies (Coralville, IA, USA). Primer
sequences are as follows: F primer: 50-ACATTTCAG
AATATCCATCCTTTGG-30; R primer: 50-TGCTAATTC
GTCCCAGAACGA-30. Probes were purchased from
Operon Biotechnologies, Inc. (Huntsville, AL,
USA). The probe 50-TGGCAGCCAAGCTAAAGCAAA
TCCTTG-30 was labeled with FAM (6-carboxy-
fluorescine) along with a quencher (BHQ 1;
Biosearch Technologies, Novato, CA, USA).
Dilutions of control gDNA of 40, 20, 10, 5 and
2.5ngml
–1 were used as comparators to test DNA
samples diluted to B10ngml
–1. All DNAs, probes and
primers were diluted in low EDTA TE buffer.
Reactions were run on the ABI 7500 Fast Real-time
PCR system (Applied Biosystems) using the following
cycling parameters: one cycle at 951C for 20s,
followed by 40 cycles at 951C for 3s and 601C for
30s. Each reaction was carried out in a total volume of
20ml containing 1  Taqman Fast Universal PCR
Master mix, 900nM of each primer and 250nM probe.
A total of 2.5ml of DNA was added to each reaction.
Reactions were carried out in triplicate. Quantitative
PCR analysis software supplied by the manufacturer
(Applied Biosystems) was used to calculate standard
curves and quantify samples. A control probe set
within the albumin gene was used as a reference to
determine copy number. A ratio of 1 for assay/
albumin was viewed as normal copy number.
Results
The ADHD cohort comprised of 335 complete parent–
child trios of European descent recruited from
pediatric and behavioral clinics that passed genotype
and CNVanalysis quality metrics (see Methods). A set
of 2026 ethnically matched, disease-free children was
used as a healthy control group. All samples were
genotyped using the Illumina HumanHap550K Bead-
Chip and a single consistent protocol. Genotype data
were uniformly analyzed for CNVs using Illumina’s
BeadStudio software in combination with a
customized adaptation of the circular binary segmen-
tation algorithm.
29
Comparison of the CNV sets identified in the 335
probands and the healthy controls showed compar-
able overall frequencies. ADHD patients had a mean
of 27.4 CNVs vs 26.9 for healthy controls (P=0.28).
No significant differences were seen for deletions
(P=0.67) or duplications (P=0.33). Moreover, no
difference was seen in CNV size between the patient
and control groups, either overall (P=0.91), or for
duplications (P=0.43) or deletions (P=0.12).
We focused on rare inherited variants matching the
following criteria: size spanning X10 consecutive
SNPs for deletions and X20 SNPs for duplications,
and present in at least one parent along with one or
more related probands but not in the healthy control
set. A total of 222 CNVs (158 deletions and 64
duplications) from 154 probands met these criteria
(Supplementary Table S1). The median variant size
was 102kb (range from 7.75 to 1775kb) with 116 of
the CNVs (52%) overlapping one or more genes. The
CNVs encompassed or overlapped 229 distinct genes,
23 of which were associated with CNVs from multiple
individuals. The largest family of genes affected was
the olfactory receptor superfamily (54 genes, includ-
ing 35 genes associated with a single duplication).
Numerous recent studies have shown that olfactory
receptors are rapidly evolving, mainly because of an
unusually high rate of structural variation and close
association of many family members with segmental
duplications.
30–32 As these genes are overrepresented
in our CNV set and present a skewed distribution that
might bias our ability to detect pathway enrichment,
these genes were removed from subsequent analyses.
This reduced our ADHD CNV gene set to 175 genes.
To determine whether the ADHD gene set prefer-
entially contained genes of neurological significance,
we first looked for evidence in the literature for prior
implication of these genes in neuropsychiatric dis-
orders. An independent, systematic assessment of
MEDLINE abstracts, HUGE Navigator, the autism gene
database AutsDB and the candidate gene database
SchizophreniaGene showed that genes implicated in
autism and/or schizophrenia in any of these resources
were significantly enriched in ADHD CNV genes
(Table 1), but not for other brain-related disorders
(Supplementary Table S2). Manual review of litera-
ture associated with the 175 genes determined that at
least 22 (28 total CNVs) of these genes were
previously implicated by genetic studies in various
neurological and neuropsychiatric disorders (Tables 2
and 3), including Tourette syndrome (two genes),
autism (four genes) and schizophrenia (15 genes).
Furthermore, eight of these 22 genes (11 total CNVs)
have been very recently identified in structural
variation studies carried out on autism and schizo-
phrenia cohorts: A2BP1, PARK2, NKAIN2, DPP6,
CNTNAP2, IMMP2L, AUTS2 and GRM7.
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enriched for particular biological and disease pro-
cesses. Using Ingenuity Pathway Analysis, the
process categories neurological disease, psychological
disorders, nervous system development and function
and behavior were among the most significantly
enriched categories in the ADHD gene set, even
after application of a multiple test correction (MTC)
(Table 4). Four of the six most highly enriched GO
Biological Process categories were learning, cell
adhesion, central nervous system development and
hindbrain development (Supplementary Table S3),
with learning and cell adhesion trending towards
statistical significance after MTC application. When
GO Biological Process analysis was restricted to genes
that overlapped only CNV deletions, the classes
representing learning and hindbrain development
retained MTC-applied significance (Table 5). ADHD
CNV genes associated with learning and cognition
included ATM, CTNND2, GRM5, GRM7, PARK2,
PTPRD and UNC13C. As an additional control to
show the specificity and independence of the inclu-
sion variables, the same CNV inclusion criteria and
analysis strategies were reapplied using a large set of
parent–child trios for congenital heart disease. The
enriched pathway spectrum was almost entirely
dissimilar in the cardiovascular cohort, and no
neurological function classes were found significant,
even without MTC application.
Several of the most highly enriched GO cellular
component terms involved neural functioning,
although no terms were sufficiently enriched to pass
significance testing after MTC application. Three
genes (GRM5, GRM7 and PARK2) were associated
with the GO term postsynaptic membrane, four genes
(GRM5, GRM7, PARK2 and UNC13C) with synapse,
two genes (CHN2 and UNC13C) with synaptosome
and two genes (CPLX2, GOSR1) with the SNARE
complex, members of which mediate synaptic vesicle
fusion.
Two genes, PTPRD and GRM5, were especially
intriguing as putative candidate genes for ADHD.
Hemizygous deletions involving the protein tyrosine
phosphatase gene, PTPRD, were detected in four
unrelated ADHD probands, spanning exon 2, exons
3–9, exon 9 and intron 2 of the gene, respectively
(Supplementary Figure S1). PTPRD CNVs were
experimentally validated by quantitative PCR in two
probands (Supplementary Table S4). The deletion
was confirmed by q-PCR in both probands as well as
in a transmitting parent for the one case where DNA
was available (130-386-1). Two of the four ADHD
probands with PTPRD deletions reported symptoms
consistent with restless legs syndrome (RLS), which
shares high rates of bidirectional comorbidity as well
as dopaminergic dysfunction with ADHD.
33,34 Intrigu-
ingly, a recent genome-wide association study has
implicated PTPRD as a locus for RLS.
35 Moreover,
genetic variants of PTPRD associate with bronchial
asthma,
36 which is reported to occur at higher rates in
children with ADHD,
37 and RLS patients have been
shown to have increased use of asthma medications.
38
Studies of the PTPRD gene in mice show high
expression in the hippocampus, the only brain region
reported to be enlarged in ADHD,
39 along with
involvement in spatial learning, long-term potentia-
tion and axonal guidance of motor neurons.
40–42
Catecholaminergic neurotransmission is widely
studied in ADHD and has yielded several candidate
genes conferring a small amount of risk, suggesting a
potential role for additional neurotransmitter sys-
tems. We found a maternally derived GRM5 CNV in
three siblings. Both GRM5 and GRM7 (above) belong
to the glutamatergic receptor gene family hypothe-
sized to play a role in ADHD.
43–45 The GRM5 variant, a
hemizygous deletion of 82kb (11 SNPs; Supplemen-
tary Figure S2), showed uniparental inheritance and
was experimentally validated by FISH (Figure 1).
Neuropsychiatric assessment indicated that all three
children in this family, one 18-year-old male and two
females with ages 15 and 11, met the criteria for
Table 2 Genes in ADHD CNVs previously associated with
neuropsychiatric and neurological disorders
Gene Disorder(s)
a Genomic
reference(s)
b
A2BP1 Schizophrenia; autism;
mental retardation
(15, 21, 55, 56)
APOL4 Schizophrenia (57)
ATM Ataxia-telangiectasia;
neurodegeneration
(58, 59)
AUTS2 Mental retardation
and autism
(60–62)
BLMH Alzheimer’s disease (63)
CHL1 Schizophrenia (64)
CHN2 Schizophrenia (65)
CNTNAP2 Schizophrenia;
autism; Tourette syndrome
(17, 58, 66–68)
CPLX2 Schizophrenia (69)
CTNND2 Mental retardation in
cri du chat syndrome
(70)
DPP6 Schizophrenia (21)
GRM5 Schizophrenia; Fragile X
syndrome
(71, 72)
GRM7 Schizophrenia (19)
IMMP2L Autism; Tourette syndrome (73–76)
NKAIN2 Schizophrenia (21)
PARK2 Schizophrenia (21)
PDCD10 Cerebral cavernous
malformations
(77)
PTPRD Restless legs syndrome (33)
RTN4 Schizophrenia (78)
SEPP1 Schizophrenia (79)
SERPINI1 Schizophrenia (80, 81)
TACR3 Schizophrenia (82)
Abbreviations: ADHD, attention-deficit/hyperactivity dis-
order; CNVs, copy number variations.
aUnderlined disorders indicate implication through CNV
analysis.
bReferences in Table 2 are listed in the Supplementary
Materials.
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hood. All three children showed some improvement
in symptoms with medications but persistent overall
dysfunction in academic, social and behavioral
spheres in spite of superior IQ levels. Assessment of
the mother using the ADHD Self-Report Scale in-
dicated a likelihood of ADHD (scores of 20 for part
A and 12 for part B).
46 The mother, and to a lesser
extent, all three children, display problems with
spatial orientation, a characteristic also observed in
the GRM5 null mouse.
47 Intriguingly, GRM5 null mice
also have deficiencies in long-term potentiation
47 as
well as an increase in anxiety-like behavior that can
be reduced with GRM5 antagonists.
48 ADHD fre-
quently occurs in Fragile X syndrome,
49 and GRM5
antagonists have recently been shown to de-repress
startle inhibition in Fragile X (FMR1) null mice.
In addition to the parent with the GRM5 variant, we
were able to obtain ADHD Self-Report Scales for an
additional 20 parents with CNVs overlapping any of
the 22 top candidate genes from Table 2 (presented in
Supplementary Table S5). Two parents (for genes
IMMP2L and A2BP1) met definitive criteria for
adulthood ADHD (score of 24 and above on either
section A or section B of the ASRS) and three parents
(for genes A2BP1, DPP6 and PTPRD) were likely to
meet criteria (ASRS score 17–23 on either section).
However, interpretation of this data is complex owing
to our limited knowledge of adult ADHD and its
relationship to the childhood form.
Discussion
The CNV-associated gene set identified in our ADHD
cohort did not have an excess of deletions or
insertions compared with the controls. It was how-
ever significantly enriched for genes reported as
candidates in other neuropsychiatric disorders and
neurodevelopmental pathways.
In addition to PTPRD and GRM5, several genes in
our ADHD CNV gene set are notable, particularly
those eight previously reported to have CNVs in
another neuropsychiatric disorder (Tables 2 and 3).
The A2BP1 gene, whose protein product binds to the
Table 3 ADHD CNVs within or overlapping genes previously implicated in neuropsychiatric and neurological disorders
Subject Chromosome Sequence
start
Sequence
end
Type
a # of base
pairs
# of single
nucleotide
polymorphisms
Gene(s)
b
130_080_3 2 55088956 55239201 dup 150246 40 RTN4
130_351_3 3 38411 1118424 dup 1080014 268 CHL1; CNTN6
130_068_3 3 7183953 7197236 het 13284 10 GRM7 (intronic)
ZBBX; SERPINI2; WDR49;
130_237_3 3 168483422 169118601 dup 635180 91 PDCD10; SERPINI1
130_083_3 4 104848417 104972885 dup 124469 25 TACR3
130_231_3 5 11540585 11571704 het 31120 13 CTNND2 (intronic)
130_340_3 5 42613316 42859556 dup 246241 22 GHR; SEPP1
130_100_3 5 175136520 175195299 het 58780 30 CPLX2
130_347_3 6 124379082 124526687 het 147606 41 NKAIN2 (intronic)
130_213_3 6 162672945 162782313 het 109369 41 PARK2 (intronic)
130_220_3 6 162699792 162801747 dup 101956 38 PARK2 (intronic)
130_401_3 7 28982601 29309947 dup 327347 155 CHN2
130_386_3 7 69624365 69726112 dup 101748 37 AUTS2
130_197_3 7 110672863 110923287 het 250425 33 IMMP2L
130_285_3 7 146179259 146237754 het 58496 12 CNTNAP2 (intronic)
130_249_3 7 153332837 153468471 het 135635 48 DPP6
130_142_3 9 9084805 9178865 het 94061 42 PTPRD
130_386_3 9 9168137 10067180 het 899044 317 PTPRD
130_087_3 9 9985938 10020458 het 34521 10 PTPRD (intronic)
130_093_3 9 10160101 10423023 het 262923 100 PTPRD
130_230_3 11 88269449 88351661 het 82213 11 GRM5 (intronic)
ACAT1; NPAT; ATM;
130_243_3 11 107520009 107885084 dup 365076 30 C11orf65; KDELC2; EXPH5
130_358_3 16 6072599 6783832 dup 711234 398 A2BP1
130_089_3 16 6753260 6841514 het 88255 44 A2BP1 (intronic)
130_214_3 16 7223181 7270339 het 47159 23 A2BP1 (intronic)
130_316_3 17 25613604 26191779 dup 578176 46 BLMH (six additional genes)
130_055_3 22 34870070 34916870 het 46801 23 APOL3; APOL4
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNVs, copy number variations.
aType of CNV: het, hemizygous deletion; hom, homozygous deletion; dup, duplication.
bGene(s) partially or fully contained within the corresponding CNV. The listed CNVis predicted to overlap one or more exons
unless indicated by (intronic), where the CNV is predicted to lie entirely within a single intron of the named gene.
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was found overlapping with three rare inherited copy
number changes in our ADHD probands, and it was
also seen in rare de novo copy number changes
involving only this gene in a schizophrenic and an
autistic proband. Translocations and CNVs disrupting
A2BP1 have been reported in patients with autism,
schizophrenia, epilepsy and mental retardation. The
PARK2, NKAIN2 and DPP6 genes were found over-
lapping with separate rare inherited copy number
changes in our study as well as in CNVs overlapping
only the same respective genes in a schizophrenia
study. Genomic deletions of the neurexin superfamily
gene, CNTNAP2, were also identified in three
individuals with schizophrenia and epilepsy. Allelic
variants of the CNTNAP2 gene have been found to be
associated with autism in three recent studies.
Chromosomal rearrangements of both the CNTNAP2
and IMMP2L genes have been reported in patients
with Tourette syndrome, and the IMMP2L gene is
present within the 7q22 AUTS1 locus identified
by several autism association studies. Similarly,
Table 4 Gene functional categories significantly enriched in ADHD CNVs using ingenuity pathway analysis
Category Genes in CNVs Significance
a Adjusted
significance
b
Diseases and disorders
Infectious disease ATG5, ATM, F7, F10, MC2R, PARK2 7.56 10
 3 2.32 10
 2
Genetic disorders ATM, EDARADD, F7, F10, GHR, HNF1B, MC2R, PARK2,
SERPINI1, TNFRSF11A, ZCCHC2
1.79 10
 4 2.95 10
 2
Psychological disorders APOL4, AUTS2, CHL1, CHN2, CNTNAP2, CPLX2, GRM5,
RTN4, SEPP1, SERPINI1, TACR3
5.28 10
 4 3.08 10
 2
Neurological disease ACAT1, APOL4, ATM, AUTS2, CHL1, CHN2, CNTNAP2,
CPLX2, F7, GRM5, MC2R, PARK2, RTN4, SEPP1,
SERPINI1, TACR3
5.28 10
 4 4.58 10
 2
Hematological disease ATM, CUBN, F7, F10, MC2R 1.79 10
 4 4.58 10
 2
Embryonic development FTO, HNF1B, IRX3, LHX1, MBTPS1, TCF21 8.82 10
 4 4.98 10
 2
Physiological system development and function
Hematological system
development and function
F7, F10, PRDM1 8.82 10
 4 1.55 10
 2
Behavior ATM, CHL1, CTNNA2, CTNND2, GRM5, GRM7, KLHL1,
PARK2, PTPRD, SEPP1, UNC13C
1.90 10
 5 2.32 10
 2
Renal and urological system
development and function
CTNND2, F7, GHR, RTN4, SDK1, TCF21 6.32 10
 4 3.83 10
 2
Nervous system development
and function
ATM, CDH4, CHL1, CHN2, CNTN6, CTNNA2, FTO,
GHR, GRM5, GRM7, IRX3, PARK2, PTPRD, RTN4, SEMA3E,
SEPP1, SERPINI1, UNC13C
3.56 10
 4 4.58 10
 2
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNVs, copy number variations.
aSingle test P-values.
bMultiple test-corrected P-values using the Benjamini–Hochberg correction; only categories reaching a corrected statistical
significance of P<0.05 are shown.
Table 5 Gene functional categories significantly enriched in ADHD CNV deletions using Gene Ontology (GO) analysis
GO term Genes in CNVs Significance
a Adjusted
significance
b
Learning CTNND2, GRM5, GRM7, PARK2 9.20 10
 5 9.48 10
 3
Response to organic substance ACACA, COLEC12, DUOX1, DUOX2, HNF1B 4.91 10
 4 1.76 10
 2
Lipoprotein metabolic process APOL3, APOL4, COLEC12, PIGW 7.16 10
 4 1.76 10
 2
Learning and/or memory CTNND2, GRM5, GRM7, PARK2 8.24 10
 4 1.76 10
 2
Hindbrain development HNF1B, KLHL1, LHX1 8.56 10
 4 1.76 10
 2
Cell adhesion AATF, CDH12, CDH4, CNTN6, CNTNAP2, CSMD1,
CTNNA2, CTNNA3, CTNND2, GMDS, PCDH21, SDK1
1.31 10
 3 2.25 10
 2
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNVs, copy number variations.
aSingle test P-values.
bMultiple test-corrected P-values using the Benjamini–Hochberg correction; only categories reaching a corrected statistical
significance of P<0.05 are shown.
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gene have been reported in five autism patients.
Finally, a rare copy number variant in a schizophrenic
patient was found to overlap with the glutamatergic
receptor GRM7. We observed an ADHD proband with
a CNV in GRM7 who also presented with anxiety. The
extinction of conditioned fear, blocked with down-
regulation of GRM7, suggests that some of these CNVs
may potentially explain certain comorbidities
frequently associated with ADHD.
50,51
Recent investigations of structural variation in
autism and schizophrenia have found increased de
novo and/or overall variation in diseased individuals,
leading to the speculation that these diseases may
have a sizable number of possible molecular etiolo-
gies.
15,19,21,52,53 To date, this theory is consistent with
the general lack of success of genetic association
studies in identifying common causative variants
in neuropsychiatric disorders, including ADHD.
54
Our results further support this hypothesis, as we
found a wide distribution of genes specifically
affected by CNVs in our ADHD probands relative to
controls, many of which were associated with
neurodevelopmental pathways and disorders.
Although our CNV detection platform is of high
resolution, common CNV regions are underrepre-
sented; it remains to be determined whether use of a
higher resolution platform or a sequencing approach
would alter the distribution curve of implicated
genes. Nevertheless, our approach has identified
a number of intriguing candidates that support a
potential role of CNVs in ADHD, and it also suggests a
number of candidate genes that may help to explain
the spectrum of phenotypic heterogeneity observed in
ADHD and other neuropsychiatric disorders.
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